204 related articles for article (PubMed ID: 28902794)
1. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
Martin JA; Warner RRP; Aronson A; Wisnivesky JP; Kim MK
Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors.
Kim MK; Warner RR; Ward SC; Harpaz N; Roayaie S; Schwartz ME; Itzkowitz S; Wisnivesky J
Neuroendocrinology; 2015; 101(1):58-65. PubMed ID: 25572143
[TBL] [Abstract][Full Text] [Related]
3. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors.
Chi W; Warner RRP; Chan DL; Singh S; Segelov E; Strosberg J; Wisnivesky J; Kim MK
Pancreas; 2018 Mar; 47(3):321-325. PubMed ID: 29401168
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
7. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
9. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
Fitzgerald TL; Mosquera C; Lea CS; McMullen M
Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
11. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
12. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
[No Abstract] [Full Text] [Related]
13. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC;
J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621
[TBL] [Abstract][Full Text] [Related]
14. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.
Cai Y; Liu Z; Jiang L; Ma D; Zhou Z; Ju H; Zhu Y
Front Endocrinol (Lausanne); 2022; 13():871830. PubMed ID: 35937823
[TBL] [Abstract][Full Text] [Related]
16. The Lymph Node Ratio Optimizes Staging in Patients with Small Intestinal Neuroendocrine Tumors.
Wu L; Chen F; Chen S; Wang L
Neuroendocrinology; 2018; 107(3):209-217. PubMed ID: 29920478
[TBL] [Abstract][Full Text] [Related]
17. A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors.
Gaitanidis A; Patel D; Nilubol N; Tirosh A; Kebebew E
J Clin Endocrinol Metab; 2018 Jan; 103(1):187-195. PubMed ID: 29069375
[TBL] [Abstract][Full Text] [Related]
18. Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors.
Shannon AB; Straker RJ; Fraker DL; Miura JT; Karakousis GC
J Am Coll Surg; 2022 May; 234(5):900-909. PubMed ID: 35426404
[TBL] [Abstract][Full Text] [Related]
19. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
